AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations
Katharine Yen(Agios Pharmaceuticals (United States)), Shinsan M. Su(Agios Pharmaceuticals (United States)), Lenny Dang(Millennium Engineering and Integration (United States)), Hua Yang(China Pharmaceutical University), Byron DeLaBarre(Agios Pharmaceuticals (United States)), Angélo Paci(Institut Gustave Roussy), Marion Dorsch(Biogen (United States)), Stéphane de Botton(Université Paris-Saclay), Jeremy Travins(Agios Pharmaceuticals (United States)), Scott A. Biller(Agios Pharmaceuticals (United States)), Erin Artin(Agios Pharmaceuticals (United States)), Véronique Saada(Université Paris-Saclay), Sung Choe(Agios Pharmaceuticals (United States)), Raj Nagaraja(Agios Pharmaceuticals (United States)), Kimberly Straley(Agios Pharmaceuticals (United States)), Cyril Quivoron(Inserm), Paule Opolon(Institut Gustave Roussy), Olivier Bernard(Université de Poitiers), Lee Silverman(Agios Pharmaceuticals (United States)), Benoît Marteyn(Centre National de la Recherche Scientifique), Anil K. Padyana(Agios Pharmaceuticals (United States)), Jeffrey O. Saunders(Agios Pharmaceuticals (United States)), Sophie Broutin(Université Paris-Saclay), Zenon Konteatis(Agios Pharmaceuticals (United States)), Giovanni Cianchetta(Agios Pharmaceuticals (United States)), Muriel D. David(Inserm), Virginie Penard‐Lacronique(Université Paris-Sud), Erica R. Tobin(Agios Pharmaceuticals (United States)), Fang Wang(Shanghai Medical College of Fudan University), Yue Chen(Capital Medical University), Lei Jin(Agios Pharmaceuticals (United States)), YingXia Xu(SciencePharma (Poland)), Wei Liu(Chinese Academy of Sciences), Cheng Fang(SciencePharma (Poland)), Fan Jiang(Peking University), Wentao Wei(Viva Biotech (China)), Stefan Größ(Agios Pharmaceuticals (United States)), Shengfang Jin(Agios Pharmaceuticals (United States)), Olivia Bawa(Université Paris-Saclay), Monika Pilichowska(Tufts Medical Center), Francesco G. Salituro(Agios Pharmaceuticals (United States))
Cited by 457
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k